-
公开(公告)号：BR112021019858A2
公开(公告)日：2021-12-07
申请号：BR112021019858
申请日：2020-04-02
Applicant: VERTEX PHARMA
Inventor： ALEXANDER RUSSELL ABELA , SILINA ALINA , BRYAN A FRIEMAN , COREY DON ANDERSON , CHAU JACLYN , MCCARTNEY JASON , CLEMENS JEREMY , ZHOU JINGLAN , UY JOHNNY , MARK THOMAS MILLER , KRENITSKY PAUL , GROOTENHUIS PETER , SARA SABINA HADIDA RUAH , ABRAHAM SUNNY , CLEVELAND THOMAS , TIMOTHY A DWIGHT , ARUMUGAM VIJAYALAKSMI , MELILLO VITO , ISHIHARA YOSHIHIRO
IPC: C07D239/69 , A61P11/00 , C07D515/08
Abstract: agentes de modulação reguladores de condutância transmembrana de fibrose cística. são divulgados o composto i, derivados deuterados e sais farmaceuticamente aceitáveis de acordo com qualquer um dos anteriores. métodos de tratamento de fibrose cística usando esses compostos também são divulgados. i
-
12.发明专利
公开(公告)号：MX2021011977A
公开(公告)日：2021-11-03
申请号：MX2021011977
申请日：2020-04-02
Applicant: VERTEX PHARMA
Inventor： MILLER MARK THOMAS , ARUMUGAM VIJAYALAKSMI , ZHOU JINGLAN , FRIEMAN BRYAN A , MCCARTNEY JASON , SILINA ALINA , KRENITSKY PAUL , CLEVELAND THOMAS , HADIDA RUAH SARA SABINA , ABELA ALEXANDER RUSSELL , UY JOHNNY , ANDERSON COREY DON , ABRAHAM SUNNY , CHAU JACLYN , CLEMENS JEREMY , DWIGHT TIMOTHY A , GROOTENHUIS (FALLECIDO) PETER , ISHIHARA YOSHIHIRO , MELILLO VITO
IPC: A61P11/00 , C07D239/69 , C07D515/08
Abstract: Se describen el compuesto I, derivados deuterados y sales farmacéuticamente aceptables de cualquiera de los precedentes. También se describen métodos para tratar la fibrosis cística usando los compuestos. (ver Fórmula).
-
公开(公告)号：PL3203840T3
公开(公告)日：2021-01-11
申请号：PL15849396
申请日：2015-10-06
Applicant: VERTEX PHARMA
Inventor： MILLER MARK THOMAS , ANDERSON COREY , ARUMUGAM VIJAYALAKSMI , BEAR BRIAN RICHARD , BINCH HAYLEY MARIE , CLEMENS JEREMY J , CLEVELAND THOMAS , CONROY ERICA , COON TIMOTHY RICHARD , FRIEMAN BRYAN A , GROOTENHUIS PETER DIEDERIK JAN , GROSS RAYMOND STANLEY , HADIDA-RUAH SARA SABINA , KHATUYA HARIPADA , JOSHI PRAMOD VIRUPAX , KRENITSKY PAUL JOHN , LIN CHUN-CHIEH , MARELIUS GULIN ERDOGAN , MELILLO VITO , MCCARTNEY JASON , NICHOLLS GEORGIA MCGAUGHEY , PIERRE FABRICE JEAN DENIS , SILINA ALINA , TERMIN ANDREAS P , UY JOHNNY , ZHOU JINGLAN
IPC: A01N41/06 , A61K31/18 , C07D209/18 , C07D209/49 , C07D213/64 , C07D213/73 , C07D231/20 , C07D235/24 , C07D239/34 , C07D401/04 , C07D403/10 , C07D403/12 , C07D407/12 , C07D413/14
-
公开(公告)号：RS60906B1
公开(公告)日：2020-11-30
申请号：RSP20201210
申请日：2015-10-06
Applicant: VERTEX PHARMA
Inventor： MILLER MARK THOMAS , ANDERSON COREY , ARUMUGAM VIJAYALAKSMI , BEAR BRIAN RICHARD , BINCH HAYLEY MARIE , CLEMENS JEREMY J , CLEVELAND THOMAS , CONROY ERICA , COON TIMOTHY RICHARD , FRIEMAN BRYAN A , GROOTENHUIS PETER DIEDERIK JAN , GROSS RAYMOND STANLEY , HADIDA-RUAH SARA SABINA , KHATUYA HARIPADA , JOSHI PRAMOD VIRUPAX , KRENITSKY PAUL JOHN , LIN CHUN-CHIEH , MARELIUS GULIN ERDOGAN , MELILLO VITO , MCCARTNEY JASON , NICHOLLS GEORGIA MCGAUGHEY , PIERRE FABRICE JEAN DENIS , SILINA ALINA , TERMIN ANDREAS P , UY JOHNNY , ZHOU JINGLAN
IPC: A01N41/06 , A61K31/18 , C07D209/18 , C07D209/49 , C07D213/64 , C07D213/73 , C07D231/20 , C07D235/24 , C07D239/34 , C07D401/04 , C07D403/10 , C07D403/12 , C07D407/12 , C07D413/14
-
15.发明专利
公开(公告)号：UY38630A
公开(公告)日：2020-10-30
申请号：UY38630
申请日：2020-04-01
Applicant: VERTEX PHARMA
Inventor： ABELA ALEXANDER RUSSELL , ANDERSON COREY DON , CLEVELAND THOMAS , GROOTENHUIS PETER , HADIDA RUAH SARA SABINA , MCCARTNEY JASON , MILLER MARK THOMAS , UY JOHNNY , ZHOU JINGLAN , ABRAHAM SUNNY , ARUMUGAM VIJAYALAKSMI , CHAU JACLYN , CLEMENS JEREMY , DWIGHT TIMOTHY A , FRIEMAN BRYAN A , ISHIHARA YOSHIHIRO , KRENITSKY PAUL , MELILLO VITO , SILINA ALINA
IPC: A61P11/00 , C07D239/42 , C07D239/70 , C07D515/22
Abstract: Se describen el compuesto I, derivados deuterados y sales farmacéuticamente aceptables de cualquiera de los precedentes. También se describen métodos para tratar la fibrosis quística utilizando dichos compuestos
-
Patent Agency Ranking
公开(公告)号：AU2020220185A1
公开(公告)日：2020-09-10
申请号：AU2020220185
申请日：2020-08-21
Applicant: VERTEX PHARMA
Inventor： MILLER MARK THOMAS , ANDERSON COREY , ARUMUGAM VIJAYALAKSMI , BEAR BRIAN RICHARD , BINCH HAYLEY MARIE , CLEMENS JEREMY J , CLEVELAND THOMAS , CONROY ERICA , COON TIMOTHY RICHARD , FRIEMAN BRYAN A , GROOTENHUIS PETER DIEDERIK JAN , GROSS RAYMOND STANLEY , HADIDA-RUAH SARA SABINA , KHATUYA HARIPADA , JOSHI PRAMOD VIRUPAX , KRENITSKY PAUL JOHN , LIN CHUN-CHIEH , MARELIUS GULIN ERDOGAN , MELILLO VITO , MCCARTNEY JASON , NICHOLLS GEORGIA MCGAUGHEY , PIERRE FABRICE JEAN DENIS , SILINA ALINA , TERMIN ANDREAS P , UY JOHNNY , ZHOU JINGLAN
IPC: C07D209/18 , A01N41/06 , A61K31/18
Abstract: The present invention features a compound of formula (I): W OZ, x z' (R1)n A B (R2)p (Y)0 C (R3)q (1) or a pharmaceutically acceptable salt thereof, where R 1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
-
公开(公告)号：CL2017000824A1
公开(公告)日：2018-01-19
申请号：CL2017000824
申请日：2017-04-04
Applicant: VERTEX PHARMA
Inventor： MILLER MARK THOMAS , ANDERSON COREY , ARUMUGAM VIJAYALAKSMI , BEAR BRIAN RICHARD , BINCH HAYLEY MARIE , CLEMENS JEREMY J , CLEVELAND THOMAS , CONROY ERICA , COON TIMOTHY RICHARD , FRIEMAN BRYAN A , GROOTENHUIS PETER DIEDERIK JAN , GROSS RAYMOND STANLEY , HADIDA RUAH SARA SABINA , KHATUYA HARIPADA , JOSHI PRAMOD VIRUPAX , KRENITSKY PAUL JOHN , LIN CHUN CHIEH , MARELIUS GULIN ERDOGAN , MELILLO VITO , MCCARTNEY JASON , NICHOLLS GEORGIA MCGAUGHEY , PIERRE FABRICE JEAN DENIS , SILINA ALINA , TERMIN ANDREAS P , UY JOHNNY , ZHOU JINGLAN
Abstract: LA PRESENTE INVENCIÓN CARACTERIZA UN COMPUESTO DE LA FÓRMULA I, LA CUAL, UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, DONDE R1, R2, R3, W, X, Y, Z, N, O, P Y Q SE DEFINEN EN LA PRESENTE, PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR CFTR, COMO FIBROSIS QUÍSTICA. LA PRESENTE INVENCIÓN TAMBIÉN CARACTERIZA COMPOSICIONES FARMACÉUTICAS, MÉTODO DE TRATAMIENTO Y SUS KITS.
-
公开(公告)号：NZ603043A
公开(公告)日：2015-02-27
申请号：NZ60304311
申请日：2011-04-22
Applicant: VERTEX PHARMA
Inventor： SHETH URVI JAGDISHBHAI , BOTFIELD MARTYN CURTIS , ALCACIO TIM EDWARD , YANG XIAOQING , SULLIVAN MARK JEFFREY , HURLEY DENNIS JAMES , AREKAR SNEHA G , KESHAVARZ-SHOKRI ALI , ZHANG BEILI , ZLOKARNIK GREGOR , KRAWIEC MARIUSZ , ALARGOVA ROSSITZA GUEORGUIEVA , ZHANG YUEGANG , BINCH HAYLEY MARIE , FANNING LEV TYLER DEWEY , JOHNSTON STEVEN C , YOUNG CHRISTOPHER RYAN , NUMA MEHDI , SILINA ALINA , GROOTENHUIS PETER DIEDERIK JAN , VAN GOOR FREDRICK F , ZAMAN NOREEN TASNEEM , MUDUNURI PRAVEEN , KAUSHIK RITU ROHIT , MEDEK ALES , KADIYALA IRINA NIKOLAEVNA , LEE ELAINE CHUNGMIN , LUISI BRIAN , VERWIJS MARINUS JACOBUS
IPC: A61K31/443 , A61K31/36 , A61K31/47 , C07D213/75 , C07D215/233 , C07D215/56 , C07D317/46
Abstract: Disclosed is a pharmaceutical composition comprising: Compound 1 SDD Formulation and Compound 3 Form I Tablet Formulation wherein: Compound 1 SDD Formulation is a spray dried dispersion of ivacaftor (VX-770), which comprises from about 45 wt% to about 85 wt% of substantially amorphous ivacaftor by weight of the dispersion, from about 14.45 wt% to about 55.55 wt% of hydroxypropylmethylcellulose acetate succinate (HPMCAS) by weight of the dispersion, and from about 0.45 wt% to about 0.55 wt% sodium lauryl sulfate (SLS) by weight of the dispersion; Compound 3 Form I Tablet Formulation comprises: crystalline form I of lumacaftor (VX-809) (characterized by one or more peaks at 15.2 to 15.6 degrees, 16.1 to 16.5 degrees, and 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation) in an amount ranging from about 20 wt% to about 80 wt% by weight of the composition; a filler comprising microcrystalline cellulose in an amount ranging from about 20 wt% to about 50 wt% by weight of the composition; a disintegrant comprising sodium croscarmellose sodium in an amount ranging from about 1 wt% to about 5 wt% by weight of the composition; a surfactant comprising sodium lauryl sulfate in an amount ranging from about 2 wt% to about 0.3 wt% by weight of the composition; a diluent comprising mannitol in an amount ranging from about 1 wt% to about 30 wt% by weight of the composition; a lubricant comprising magnesium stearate in an amount ranging from about 0.3 wt% to about 5 wt% by weight of the composition; and at least one of: a binder comprising polyvinylpyrrolidone in an amount ranging from about 0.1 wt% to about 5 wt% by weight of the composition and a glidant comprising colloidal silica in an amount ranging from about 0.05 wt% to about 2 wt% by weight of the composition. Also disclosed is the use of the pharmaceutical composition as defined above in the manufacture of a medicament for treating a CFTR mediated disease in a human, wherein the CFTR mediated disease is selected from cystic fibrosis, COPD, emphysema, dry-eye disease or osteoporosis.
-
公开(公告)号：ZA201103411B
公开(公告)日：2012-09-26
申请号：ZA201103411
申请日：2011-05-10
Applicant: VERTEX PHARMA
Inventor： CHARRIER JEAN-DAMIEN , DURRANT STEVEN , KAY DAVID , O'DONNELL MICHAEL , KNEGTEL RONALD , MACCORMICK SOMHAIRLE , PINDER JOANNE , VIRANI ANISA , YOUNG STEPHEN , BINCH HAYLEY , CLEVELAND THOMAS , FANNING LEV T D , HURLEY DENNIS J , JOSHI PRAMOD , SHETH URVI , SILINA ALINA , REAPER PHILIP MICHAEL
IPC: C07D20060101 , A61K20060101 , A61P20060101
-
公开(公告)号：AU2010327993A1
公开(公告)日：2012-07-12
申请号：AU2010327993
申请日：2010-12-10
Applicant: VERTEX PHARMA
Inventor： SHETH URVI , FANNING TEV T D , NUMA MEHDI , BINCH HAYLEY , HURLEY DENNIS JAMES , ZHOU JINGLAN , HADIDA RUAH SARA S , HAZLEWOOD ANNA R , SILINA ALINA , VAIRAGOUNDAR RAJENDRAN , VAN GOOR FREDRICK F , GROOTENHUIS PETER DIEDERIK JAN , BOTFIELD MARTYN C
IPC: C07D215/56 , A61K31/4709 , A61P11/00 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/08
Abstract: The present invention relates to 4 -oxo- lH-quinoline- 3 carboxamides as modulators of ATP -Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present Invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
-
-
-
-
-
-
-
-
-
Search Results
126
records
(took 0.025 seconds)
